The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Mpox
MDHHS is updating webpages and materials with the term “mpox” to reduce stigma and other issues associated with prior terminology. This change is aligned with the recent World Health Organization decision and supported by the CDC.
Mpox is a disease caused by infection with the mpox virus. Mpox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus. Mpox is not related to chickenpox.
Vaccine Availability
Beginning April 1, 2024, the JYNNEOS mpox vaccine has been commercialized. Providers must now order vaccine for their patients. Please contact a participating provider regarding eligibility for the vaccine.
Note that local health departments may contact individuals who are identified as a close contact to an mpox case about getting the vaccine. If you know you had contact with someone with mpox, please contact your local health department for more information.
Please contact your physician, local pharmacy, health department or community health center for mpox vaccine availability.
Signs and Symptoms
Mpox is contagious when a rash is present and up until scabs have fallen off. Symptoms generally appear one to two weeks after exposure and infection, and the rash often lasts two to four weeks. Persons experiencing mpox symptoms should contact their health care provider for evaluation. While many of those affected in the current global outbreaks are men who have sex with men, anyone who has been in close contact with someone who has mpox can get the illness.
Providers
Treatment
There are no treatments specifically for mpox infections. However, mpox and smallpox viruses are genetically similar, which means that antiviral drugs and vaccines developed to protect against smallpox can be used to prevent and treat mpox infections.
Providers and patients are encouraged to access mpox treatment, TPOXX, via the National Institute of Allergy and Infectious Diseases’ (NIAID) clinical trial, STOMP. Adults and children of any age with mpox are eligible to enroll in the trial.
Additional information for providers and health departments is available through the linked TPOXX (Tecovirimat) Operational Planning Guide – Information for Providing Therapeutics for Persons with MPOX.